Dr. Shanza Waseem is a PhD candidate in Gynecology and Obstetrics at West China Second University Hospital, Sichuan University. Her research focuses on precision oncology and targeted therapies for solid tumors, with particular emphasis on KRAS-driven malignancies. She has extensive experience in structure-based drug design, preclinical pharmacology, and early-phase clinical trial implementation. Dr. Waseem has contributed to the development of next-generation KRAS inhibitors from bench characterization through first-in-human studies. Her work bridges laboratory discovery and clinical translation, aiming to expand therapeutic options for patients with historically undruggable targets. She has presented her findings at international oncology conferences and authored several publications in the field of molecular targeted therapies.